U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H38N2O5
Molecular Weight 530.6545
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CORTIVAZOL

SMILES

[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]3([H])[C@@]2([H])C=C(C)C4=CC5=C(C[C@]34C)C=NN5C6=CC=CC=C6

InChI

InChIKey=RKHQGWMMUURILY-UHRZLXHJSA-N
InChI=1S/C32H38N2O5/c1-18-11-23-25-12-19(2)32(38,28(37)17-39-20(3)35)31(25,5)15-27(36)29(23)30(4)14-21-16-33-34(26(21)13-24(18)30)22-9-7-6-8-10-22/h6-11,13,16,19,23,25,27,29,36,38H,12,14-15,17H2,1-5H3/t19-,23+,25+,27+,29-,30+,31+,32+/m1/s1

HIDE SMILES / InChI

Molecular Formula C32H38N2O5
Molecular Weight 530.6545
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

The phenylpyrazosteroid cortivazol is a selective agonist ligand for the glucocorticoid receptor (GR), a steroid receptor member of the nuclear receptor superfamily of transcription factors. Cortivazol is an apoptotic, anti-inflammatory and immunosuppressive agent that has been used in the treatment of diskogenic radiculopathy, back pain, osteoarthritis and acute childhood lymphoblastic leukemia. Cortivazol has potent antileukemic activity in childhood ALL. Its activity is related to cell cycle arrest and induction of apoptosis. Cortivazol (Altim) is indicated in rheumatological diseases: - In intra-articular injection: inflammatory arthritis, advanced osteoarthritis. - In periarticular injection: tendinitis, bursitis. - In injection of soft tissue: talalgia, carpal tunnel syndrome, Dupuytren’s contracture. - In epidural injection: radiculalgia

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ALTIM

Approved Use

This product is indicated in rheumatological diseases: - In intra-articular injection: inflammatory arthritis, advanced osteoarthritis. - In periarticular injection: tendinitis, bursitis. - In injection of soft tissue: talalgia, carpal tunnel syndrome, Dupuytren’s contracture. - In epidural injection: radiculalgia
Primary
ALTIM

Approved Use

This product is indicated in rheumatological diseases: - In intra-articular injection: inflammatory arthritis, advanced osteoarthritis. - In periarticular injection: tendinitis, bursitis. - In injection of soft tissue: talalgia, carpal tunnel syndrome, Dupuytren’s contracture. - In epidural injection: radiculalgia
PubMed

PubMed

TitleDatePubMed
Synthesis of halogen-substituted pyridyl and pyrimidyl derivatives of [3,2-c]pyrazolo corticosteroids: strategies for the development of glucocorticoid receptor mediated imaging agents.
2002 Nov 21
Better results with rhenium-186 radiosynoviorthesis than with cortivazol in rheumatoid arthritis (RA): a two-year follow-up randomized controlled multicentre study.
2004 Sep-Oct
Tachon's syndrome (suracute back and/or thoracic pain following local injections of corticosteroids). A report of 318 French cases.
2005 Jan
[The contribution of capsular distension to the treatment of primary adhesive capsulitis of the shoulder: a comparative study versus rehabilitation].
2008 Dec
[Evaluation of the efficacy of CT-guided epidural and transforaminal steroid injections in patients with diskogenic radiculopathy].
2008 Jun
Effectiveness of radiation synovectomy with samarium-153 particulate hydroxyapatite in rheumatoid arthritis patients with knee synovitis: a controlled randomized double-blind trial.
2009
Four cases of coccygeal disk calcification after cortivazol injection.
2009 Dec
Ligand-based gene expression profiling reveals novel roles of glucocorticoid receptor in cardiac metabolism.
2009 Jun
Patents

Sample Use Guides

300 ugrams of cortivazol is equivalent in anti-inflammatory activity to about 5 mg of prednisolone. It is given in the treatment of musculoskeletal and joint disorders by intra-articular, periarticular, or epidural injection in doses of about 1.25 to 3.75 mg, usually at intervals of 1 to 3 weeks.
Route of Administration: Other
In Vitro Use Guide
Incubation of ICR 27 cells with cortivazol caused 50% growth inhibition and 50% maximal induction of glutamine synthetase activity at concentrations of 20 and 35 nM, respectively.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:16:27 GMT 2023
Edited
by admin
on Fri Dec 15 15:16:27 GMT 2023
Record UNII
YM183K0H63
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CORTIVAZOL
INN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
CORTIVAZOL [MART.]
Common Name English
CORTIVAZOL [MI]
Common Name English
CORTIVAZOL [USAN]
Common Name English
2'H-PREGNA-2,4,6-TRIENO(3,2-C)PYRAZOL-20-ONE, 21-(ACETYLOXY)-11,17-DIHYDROXY-6,16-DIMETHYL-2'-PHENYL-, (11.BETA.,16.ALPHA.)-
Common Name English
11.BETA.,17,21-TRIHYDROXY-6,16.ALPHA.-DIMETHYL-2'-PHENYL-2'H-PREGNA-2,4,6-TRIENO(3,2-C)PYRAZOL-20-ONE 21-ACETATE
Common Name English
NSC-80998
Code English
cortivazol [INN]
Common Name English
Cortivazol [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C521
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
WHO-VATC QH02AB17
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
WHO-ATC H02AB17
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
Code System Code Type Description
CAS
1110-40-3
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
PRIMARY
NSC
80998
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
PRIMARY
INN
2882
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
PRIMARY
SMS_ID
100000084250
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
PRIMARY
WIKIPEDIA
Cortivazol
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
PRIMARY
ECHA (EC/EINECS)
214-175-8
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
PRIMARY
FDA UNII
YM183K0H63
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
PRIMARY
MESH
C005924
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
PRIMARY
NCI_THESAURUS
C80812
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
PRIMARY
PUBCHEM
66249
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
PRIMARY
MERCK INDEX
m3797
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
PRIMARY Merck Index
DRUG BANK
DB13003
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
PRIMARY
DRUG CENTRAL
736
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
PRIMARY
ChEMBL
CHEMBL2105842
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
PRIMARY
EVMPD
SUB06809MIG
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
PRIMARY
RXCUI
21660
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
PRIMARY RxNorm
EPA CompTox
DTXSID40149442
Created by admin on Fri Dec 15 15:16:27 GMT 2023 , Edited by admin on Fri Dec 15 15:16:27 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY